U-LABA/ICS Effects on Exercise Performance, Vilanterol

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Exercise Performance

In brief

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate

Key facts

Study ID

NCT06066606

Run by

Morten Hostrup, PhD

People needed

30

Starts

2023-10-03

Expected to finish

2026-12-01

Last updated by the study team

2025-04-10

Who can join

Age: 18 and older, up to 39. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-39
• Physically active > 5 h weekly
• Maximal oxygen consumption classified as high or very high

You may not qualify if…

• Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
• ECG abnormality
• ACQ score > 1.5
• Severe bronchial hyperreactivity as determined by mannitol test
• FEV1/FVC ratio < 0.7 determined with spirometry
• Chronic illness determined to be a potential risk for participant during study
• In chronic treatment with medication that may interfere with study results
• Pregnancy
• Smoker
• Blood donation during the past 3 months

Where it is running

• August Krogh Building — Copenhagen, DK, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.